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Abstract
Background: The nutritional status and health of mothers influence the growth and development of infants during
pregnancy and postnatal life. Interventions that focus on improving the nutritional status and lifestyle of mothers
have the potential to optimise the development of the fetus as well as improve the health of mothers themselves.
Improving the diets of women of childbearing age is likely to require complex interventions that are delivered in a
socially and culturally appropriate context. In this study we aim to test the efficacy of two interventions: behaviour
change (Healthy Conversation Skills) and vitamin D supplementation, and to explore the efficacy of an intervention
that combines both, in improving the diet quality and nutritional status of pregnant women.
Methods/design: Women attending the maternity hospital in Southampton are recruited at between 8 and 12 weeks
gestation. They are randomised to one of four groups following a factorial design: Healthy Conversation Skills support
plus vitamin D supplementation (1000 IU cholecalciferol) (n = 150); Healthy Conversation Skills support plus
placebo (n = 150); usual care plus vitamin D supplementation (n = 150); usual care plus placebo (n = 150).
Questionnaire data include parity, sunlight exposure, diet assessment allowing assessment of diet quality, cigarette and
alcohol consumption, well-being, self-efficacy and food involvement. At 19 and 34 weeks maternal anthropometry is
assessed and blood samples taken to measure 25(OH) vitamin D. Maternal diet quality and 25(OH) vitamin D are the
primary outcomes. Secondary outcomes are women’s level of self-efficacy at 34 weeks, pregnancy weight gain, women’s
self-efficacy and breastfeeding status at one month after birth and neonatal bone mineral content, assessed by DXA
within the first 14 days after birth.
Discussion: This trial is evaluating two approaches to improving maternal diet: a behaviour change intervention
and vitamin D supplementation. The factorial design of this trial has the advantage of enabling each intervention
to be tested separately as well as allowing exploration of the synergistic effect of both interventions on women’s
diets and vitamin D levels.
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Background
The nutritional status and health of mothers influence
the growth and development of infants during pregnancy
and postnatal life [1]. Growth and development at these
stages of the lifecourse will influence the risk of non-
communicable diseases such as cardiovascular disease and
obesity in adulthood. Interventions that focus on improv-
ing the nutritional status and lifestyle of mothers have the
potential to optimise the growth and development of the
fetus as well as improve the health of mothers themselves.
Studies have shown that maternal nutrition influences
child body composition [2, 3]. There are two principal ap-
proaches to improving the nutritional status of pregnant
women: nutritional supplementation (multiple-micronu-
trient supplementation as well as single vitamin sup-
plements to correct deficiencies) or behaviour change
interventions that aim to improve the diet quality of
pregnant women [4]. Improving the diets of women
of childbearing age is likely to require complex inter-
ventions that are delivered in a socially and culturally
appropriate context [5].
Multiple-micronutrient approaches have improved
maternal and birth outcomes in studies of pregnant
women in developing countries [6]. In Mumbai, India,
for example, a food-based multiple-micronutrient sup-
plement started preconceptionally and given throughout
pregnancy halved the prevalence of maternal gestational
diabetes [7]. Correction of specific vitamin deficiencies
during pregnancy has improved outcomes for pregnant
women and their babies in developed and developing
country settings [8]. In a recent UK multi-centre trial of
vitamin D supplementation during pregnancy, the
Maternal Vitamin D Osteoporosis Study (MAVIDOS),
supplementation corrected maternal vitamin D defi-
ciency and optimised infant levels of vitamin D [9, 10].
Behaviour change approaches during pregnancy have
the potential to improve the health behaviours of preg-
nant women and, whereas nutrient supplementation ad-
dresses specific nutrient deficiencies, behaviour change
approaches can improve overall diet quality. Most
pregnant women want to do their best for their baby,
and so pregnancy presents an opportunity to tackle un-
healthy lifestyle choices, such as smoking, and to pro-
mote healthy ones, such as intention to breastfeed [11].
Women’s confidence or self-efficacy that they can make
such changes is an important determinant of whether
their health behaviours will improve [12]. Low levels of
self-efficacy are a barrier to healthful eating among
women from disadvantaged backgrounds [13], and many
studies have demonstrated a relationship between higher
levels of self-efficacy and better dietary behaviours [14].
Reviews of evidence have provided useful insights into
the features of behaviour change interventions associ-
ated with effectiveness in women of childbearing age
and disadvantaged groups: providing information on
risks and benefits of health behaviours combined with
goal setting and continued support after the initial
intervention were more likely to lead to behaviour
change [15, 16].
The evidence points to the need for empowerment
approaches that work by improving the self-efficacy of
participants. We applied such an approach to an inter-
vention which aimed to improve the health behaviour of
women from disadvantaged backgrounds, a group in
which there is an established link between low self-
efficacy and poor quality diet [13, 17]. The intervention,
the Southampton Initiative for Health (SIH), aimed to
improve the diets of women from disadvantaged back-
grounds. The intervention involved training Sure Start
Children’s Centre staff, who work with women and chil-
dren from disadvantaged families, in skills to support
behaviour change [18]. The training led to changes in
the way the staff interacted with women and, one year
after training, staff in the intervention area were still
using these skills and were using them significantly more
than staff in the control area [19]. Evaluation showed
that the intervention had a protective effect on the sense
of control and self-efficacy of women who came into
contact with trained staff, intermediate factors on the
causal pathway between exposure to the intervention
and change in diet and physical activity, though an influ-
ence on diet was not observed [20]. These findings
suggested that the intervention has the potential to im-
prove health behaviours in settings that offer women
greater and more frequent exposure to trained staff.
Pregnancy and childbirth offer such a setting.
Evidence from two recent UK trials supports the
potential of behaviour change interventions during preg-
nancy to improve the healthfulness of women’s diets. In
the UPBEAT and LIMIT trials, women received regular
support from health care workers throughout their preg-
nancies. In LIMIT, the intervention was informed by
stage theories of health decision making and comprised
advice on behavioural strategies for healthful eating and
increased physical activity that was delivered by a re-
search dietician and trained research assistants. Women
were encouraged to set diet and exercise goals and to
self-monitor their progress towards these goals [21]. In
UPBEAT, the intervention was informed by social cogni-
tive theory. Health trainers delivered eight weekly
sessions in which women received advice on improving
diet and physical activity through a range of strategies,
including identification of barriers to change, setting of
SMART goals and self-monitoring [22]. These behaviour
change interventions led to improvements in diet,
although they did not improve the primary outcomes of
gestational diabetes and babies born large for gestational
age [21, 22]. Importantly, both interventions adopted
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empowerment approaches, suggesting that such an
approach is likely to be successful in bringing about
behaviour change.
Given that both supplementation and behaviour
change intervention approaches have led to improve-
ments in the diets of pregnant women, it is possible that
interventions that combine both approaches might have
a greater impact on diet than when each is delivered on
its own. Evidence of the importance of self-efficacy as a
predictor of women’s diets indicates that interventions
that are effective in improving maternal diet will need to
take account of women’s social circumstances and the
barriers to healthy eating that they experience in their
daily lives. This suggests that complex multi-component
interventions will be required to bring about the sort of
changes in women’s diets that are important for the
health of their babies and has led us to assess such a
multi-component intervention using a factorial design.
In the Southampton PRegnancy Intervention for the
Next Generation (SPRING) trial, we have combined a
behaviour change approach with vitamin D supplemen-
tation. We believe that this approach to improving
health behaviour through enhancement of women’s self-
efficacy has the potential to address barriers to taking
supplements during pregnancy as well as to improve
overall dietary quality.
Aims
There are three aims of this trial. The first is to assess
the efficacy of a behaviour change intervention (Healthy
Conversation Skills) in improving the diet quality of
pregnant women. The second is to assess the efficacy of
oral daily vitamin D supplementation in improving the
vitamin D status of pregnant women. The third is to ex-
plore the efficacy of an intervention combining vitamin
D supplementation and behaviour change support in
improving the diet quality and nutritional status of preg-
nant women.
Study design
The study is a randomised controlled trial that uses a
two-by-two factorial design. The two interventions being
tested are exposure to nurses trained in skills to support
behaviour change (Healthy Conversation Skills) and daily
oral vitamin D supplementation (1000 IU cholecalciferol
daily). The women taking part in the study and the
research nurses delivering the intervention are blind to
the vitamin D intervention, so this part of the trial is
double blind. However, the same is not possible for the
behaviour change intervention. There are four groups of
study participants:
 Healthy Conversation Skills support plus vitamin D
supplementation
 Healthy Conversation Skills support plus placebo
 Usual care plus vitamin D supplementation
 Usual care plus placebo.
Primary outcomes
Given the factorial design of the trial, there are two
primary outcomes:
 Maternal circulating plasma 25(OH) vitamin D
concentration at 34 weeks
 Maternal diet quality at 34 weeks gestation assessed
with a 20-item food frequency questionnaire [23]
Secondary outcomes
The secondary outcomes are:
 Women’s level of self-efficacy at 34 weeks, assessed
with the General Self-Efficacy scale [24]
 Pregnancy weight gain assessed by gain in weight
between recruitment and 34 weeks gestation
 Maternal diet quality one month after birth
 Breastfeeding status one month after birth (yes/no)
 Neonatal whole body bone mineral content (BMC),
lean and fat mass within 2 weeks after birth assessed
by dual-energy X-ray absorptiometry (DXA).
Methods/design
The trial procedures are summarised in Fig. 1.
Study setting
The setting for the trial is the Princess Anne Maternity
Hospital, Southampton, UK. Southampton is a relatively
deprived city on the south coast of England and is
among the 25 % most deprived local authorities within
the UK based on the Index of Multiple Deprivation.
Princess Anne Hospital is the setting for the majority of
births within the city and provides maternity care for
5000 women each year.
Recruitment at 8–12 weeks
Women are recruited to the study in early pregnancy,
and by around 12 weeks if possible, using an approach
that has been successful in the MAVIDOS trial of vita-
min D supplementation during pregnancy [9]. Posters in
general practitioner (GP) surgeries and in the maternity
hospital waiting area publicise the study. Each woman
booked for her antenatal care at Princess Anne Hospital
is sent an information leaflet outlining the study along
with the routine letter she receives inviting her to her
nuchal translucency or early dating scan. Research
nurses approach women who are attending the Princess
Anne Hospital for their nuchal translucency or dating
scan between 8 and 12 weeks gestation and invite them
to discuss the study, having first checked whether they
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have read the SPRING information leaflet. If women
agree to take part, then the nurses check their eligibility
for the study and take them through the consent
process. An interpreter can be involved if required.
Women who decline to take part in the study are given
an information sheet explaining that we are running a
sub-study about why women do not take part in research.
They are asked whether they would be willing to complete
a one-page questionnaire giving details about their age,
educational attainment and number of children, and to
indicate the reasons why they declined to take part in the
study. It is made clear to women that they are under no
obligation to complete the questionnaire. They are also
asked whether they would be willing to take part in a 30-
minute interview with a researcher to further explore their
reasons for declining.
Healthy Conversation Skills support
Healthy Conversation Skills training is underpinned by
Bandura’s social cognitive model, which proposes indi-
vidual self-efficacy as central to the process of the adop-
tion and maintenance of positive health behaviours.
Higher self-efficacy is strongly associated with more
healthful behaviours [25]. The training aims to enhance
health and social care practitioners’ self-efficacy to
address a range of lifestyle issues and support patients
Fig. 1 Trial summary: Southampton PRegnancy Intervention for the Next Generation (SPRING)
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and clients to change. Empowering individuals to iden-
tify solutions and take first steps towards their goals pro-
vides mastery experiences which Bandura proposes is
one mechanism for raising self-efficacy.
Healthy Conversation Skills support is delivered by
trained research nurses. The trial has a team of six part-
time research nurses: three who have contact with women
in the intervention group and three who have contact with
women in the control group. Intervention nurses receive
training in Healthy Conversation Skills. These are skills
that support behaviour change, thus enabling practitioners
to empower women to change their own health behav-
iours. The training promotes the development of practi-
tioner skills in reflecting, listening and asking ‘open
discovery questions’: those that generally begin with ‘what’
or ‘how’. These questions, when used in conversation,
allow a client to explore an issue, identify barriers, gener-
ate solutions and set goals. Skills in Specific, Measurable,
Action-oriented, Realistic, Timed, Evaluated, Reviewed
(SMARTER) goal setting are also developed during the
training to enable practitioners and clients to review pro-
gress towards meeting goals at each successive meeting.
As such, Healthy Conversation Skills training has been de-
veloped to incorporate the use of a range of behaviour
change techniques (BCTs) [26]. These are used through-
out the training sessions, and trainees are introduced to
many of them explicitly in some of the training activities.
The training programme is described in more detail in
Table 1. Control group nurses are trained in study proce-
dures but do not have any specific training in skills to sup-
port behaviour change and so do not use open discovery
questions or support women to set goals.
Once HCS nurses are trained, they are supported to
embed the skills rapidly into their practice. Ongoing
support is provided by the HCS trainers, who are mem-
bers of the research team, during regular meetings. Every
interaction between nurses and participants is recorded
in a Case Report Form, and a sample of appointments
for each nurse are audio-recorded and assessed in detail
as part of the process evaluation. This approach will
allow us to capture variations between nurses.
The objective of having a Healthy Conversation is to
explore the woman’s world and support her to identify
issues, solutions and goals. She is therefore supported by
the trained research nurses to review these topics at
each visit. Progress with any previously set goals is
explored, and if women wish to change or set new/add-
itional goals, this is entirely acceptable and is recorded
by the nurses. A Case Report Form is completed for
every participant by each nurse at each visit to record all
goals set and the women’s experiences in working
towards and achieving these goals, as well as any barriers
and unsuccessful attempts to change. The women can
set as many or as few goals as they wish.
During the trial, the group of women randomised to
receive the behaviour change intervention will meet with
a nurse trained in Healthy Conversation Skills on four
occasions during pregnancy and once after birth. The
control group will have the same number of contacts.
Vitamin D supplementation
Vitamin D supplementation consists of a daily oral
supplement of 1000 IU cholecalciferol. Each woman re-
ceives a single box of blister-packed capsules of vitamin
D or placebo to last for the duration of her pregnancy.
Each pack is individually prescribed for each participant.
The trial’s pharmacist allocates a pack to that prescrip-
tion, documenting both the pack number and the
SPRING participant’s unique ID number. These are
checked again by the research nurse, who collects them
from pharmacy ready to issue to participants at the
14 week visit, and documented in the participant’s notes.
The medication comes with a tear-off adhesive label
which is placed in the notes as an added safeguard
against error in pack allocation. A sticker is applied to
the obstetric notes of women taking part in the trial in
order to alert clinicians to their enrolment. An informa-
tion sheet and copy of the consent form are filed in each
Table 1 Healthy Conversation Skills (HCS) training description
Communication is enhanced through practitioners developing the skill of
asking open-ended questions, known as Open Discovery Questions: those
that generally begin with ’how’ and ’what’. Such Healthy Conversations
allow a patient or client to explore an issue, identify barriers and generate
solutions that can be reviewed with the practitioner. Training aims to
increase self-efficacy and a sense of control of both practitioners and their
patients and clients.
The five core skills are:
1. To be able to identify and create opportunities to hold Healthy
Conversations
2. To use Open Discovery Questions to support someone to explore
issues, barriers and priorities; problem-solve; generate solutions; and
set goals for change
3. To reflect on practice and conversations
4. To spend more time listening than giving information or making
suggestions
5. To support someone to make a SMARTER (Specific, Measurable,
Action-oriented, Realistic, Timed, Evaluated, Reviewed) plan.
Healthy Conversation Skills training generally consists of two 3–4 hour
group sessions over a week or so to allow time for practising and
reflecting on skills between sessions. Training is delivered by an HCS
trainer experienced in group work and behaviour change to a group of
about 8 to 15 trainees. This can be followed by a period of ongoing
support, which might include a phone call or face-to-face visit from one
of the trainers to find out how skills are being implemented in practice.
The phone call and visit allow trainees to reflect on the training, how
they have implemented new skills, any barriers to their implementation
and plans for continued or increased use, including embedding self and
peer reflection as part of normal practice. Both follow-up activities are
also opportunities to collect evaluation data to assess the effectiveness
of the training in changing staff practice, using customised tools
developed by the HCS team.
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woman’s notes. The mother (with a copy to the father) is
given contact details for the study co-ordinator and re-
search nurse and asked to inform them immediately
when labour begins.
The Investigational Medicinal Product (IMP) and
matched placebo are manufactured by Sharp Clinical
Services (UK) Ltd, Crickhowell, Powys, Wales NP8 1DF,
UK. The manufacturer has no role in the trial other than
supply of the randomised IMP. As with the MAVIDOS
trial, the IMP capsules contain 1000 international units
(IU) of cholecalciferol (vitamin D3, supplied by Merck
KGaA, Darmstadt, Germany, who also had no other role
in the trial), with excipients matched to the placebo cap-
sule [9]. Study medication (active/placebo) is supplied to
the local pharmacy pre-randomised 1:1 by the manufac-
turer, using a computer system, and sequentially num-
bered for storage and dispensing. Code-break envelopes
are supplied to the lead pharmacist but are not available
to the investigative team. Emergency code-break access
is available through the principal investigator and on-call
pharmacist.
Randomisation
Consistent with the trial’s factorial design, women are
randomised to receive Healthy Conversation Skills sup-
port or to usual care and to receive a vitamin D supple-
ment or a matched placebo. The impartial trial data
manager uses block randomisation to allocate partici-
pants to receive support from a practitioner trained in
Healthy Conversation Skills, or to usual care. Blocks of 4
are used, each with two 0’s and two 1’s. This ensures
that for each 4 participants randomised there will be
equal distribution of intervention and control partici-
pants. While is it not possible to blind staff to the
allocation of Healthy Conversation Skills, the women
themselves will not be told what the intervention en-
tails and so will be blind to the intervention they are re-
ceiving. The IMP is pre-randomised by the
manufacturer using a computer system. The women are
blind to their vitamin D allocation, as are the research
team.
Early pregnancy
At around 14 weeks gestation women attend the re-
search clinic at Princess Anne Hospital. The timing of
this appointment can be later if they are not recruited by
14 weeks. During the appointment, an interviewer-led
questionnaire is administered to gather information on
parity, baseline demographic features, diet, smoking, al-
cohol intake, exercise, sunlight exposure, general health,
medication, psychological health and wellbeing, self-
efficacy and food involvement. Diet is assessed using a
20-item food frequency questionnaire (FFQ) which was
developed from a larger FFQ [23]. Data from the FFQ
are used to produce a standardised score (with mean 0
and standard deviation 1.0). This score has been named
the ‘prudent diet score’. The 20-item FFQ gives closely
comparable scores to the full FFQ and can be used in
settings where administration of a longer FFQ is not
feasible.
For women in the Healthy Conversation Skills inter-
vention group, this appointment also presents an oppor-
tunity for the first Healthy Conversation with a trained
research nurse. Women are asked about their lifestyle
and health behaviours and what they would like to do to
ensure they have healthy pregnancies and healthy babies,
and to set some goals for achieving this. Details of the
conversations and goals are recorded in a Case Report
Form and revisited at future appointments.
Women’s height, weight, skinfold thickness (triceps,
biceps, subscapular and suprailiac) and grip strength are
measured. Venous blood samples are taken and stored
with the aim of measuring biomarkers of quality of diet,
including beta carotene and vitamin D. With partici-
pants’ consent, blood pellets are stored to allow future
DNA analysis.
18–21 weeks gestation
Women attend at 18–21 weeks for a National Health
Service (NHS) fetal anomaly scan and an additional
high-resolution 3D ultrasound scan to obtain detailed
measurements of their pregnancies. These scans are per-
formed by the SPRING study sonographer. If any abnor-
malities are identified, women are referred to their local
fetal medicine department for further management and
might be excluded from this trial if the diagnosis would
make it difficult for them to continue either with the
IMP or the study procedures. The findings of any abnor-
mal scans will be recorded as adverse events and thus
might inform potential new hypotheses regarding the
action of vitamin D in pregnancy. A pill count is per-
formed to assess compliance with the study.
During the 18–21 weeks visit, and after the scan, the
intervention research nurses hold a second Healthy
Conversation with women in the Healthy Conversation
Skills intervention groups to discuss their pregnancies,
explore progress towards any goals they set at the
14 week visit and to set new ones if need be. Details of
conversations are recorded on the Case Report Form.
This forms part of the implementation component of
process evaluation. Control research nurses give control
group women an information sheet and confirm the
timing of the 26 week phone call.
26 weeks gestation
At 26 weeks gestation, all women taking part in the trial
receive a phone call from the research nurses. Healthy
Conversation Skills intervention women are phoned by
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intervention nurses who hold a Healthy Conversation
with them and explore progress towards their goals.
Women in the normal care control group receive calls
from control group nurses. The call is used to check
personal details and confirm the time of their next ap-
pointment. All calls, to both intervention and control
women, are audio-recorded to inform the evaluation of
intervention implementation.
34 weeks gestation
Women attend the research clinic at 34 weeks gesta-
tion for a repeat growth and 3D ultrasound scan,
questionnaire and blood tests. Those in the Healthy
Conversation Skills intervention group have a Healthy
Conversation with an intervention research nurse to
monitor their goals and offer support. Women in the
control group have contact with control group nurses
and receive standard antenatal care. Questionnaires
administered at this visit assess intake of foods and
supplements containing vitamin D, smoking, alcohol,
exercise, medications, health, well-being and self-
efficacy. Venous blood samples taken at this visit are
used to measure 25(OH) vitamin D, calcium, alkaline
phosphatase, albumin and dietary biomarkers such as
beta carotene and vitamin C. Any woman found to
be hypercalcaemic (serum calcium >2.75 mmol/l) is
followed up and managed appropriately. Compliance
with the study medication is assessed by pill count.
Mothers are given an information sheet about the
neonatal DXA scan at this visit.
Admission to hospital for labour
The study co-ordinator/research nurse is informed of
any women entering labour by the NHS midwives or by
the women themselves or their partners. The attending
midwives collect venous umbilical cord blood (including
samples for genetic analyses) and placental and umbilical
cord tissue samples at delivery. The tissue samples will
allow exploration of the effect of vitamin D supplemen-
tation on calcium transport across the placenta. After
ensuring the infant’s hips have been assessed by a
paediatrician to exclude congenital hip dislocation, a
research nurse measures the baby’s length, weight, skin-
folds and abdominal circumference, and arranges an
appropriate time for the baby to undergo bone density
assessment by DXA.
Neonatal DXA
Infants receive DXA scans within the first 2 weeks after
delivery. The reliability of DXA measurements in neo-
nates has been demonstrated in the Southampton
Women’s Survey [2]. The baby is pacified, fed, fully un-
dressed and then swaddled in a towel before being
placed on the densitometer (Hologic Discovery
instrument using paediatric software (Hologic Inc., Bed-
ford, MA, USA)). The scanner is calibrated against a
spine phantom every day together with daily quality as-
surance and step-wedge calibration, performed as per
manufacturer’s instructions (Hologic Inc., Bedford, MA,
USA). If possible, the baby is scanned while still an in-
patient. If this is not possible, the mother and baby re-
turn for assessment within 14 days of birth. Whole body
and lumbar spine bone area, bone mineral content and
bone mineral density are measured. The infant DXA as-
sessments are associated with a low dose of radiation ex-
posure, roughly equivalent to 2 days of background
radiation in Cornwall (UK) and 7 days in other parts of
the UK.
One month after birth
Mothers and their babies are visited at home by an inter-
vention or control nurse, depending on their allocation
to Healthy Conversation Skills. Questionnaires are ad-
ministered repeating the questions used at 34 weeks but
also asking questions about infant feeding in order to es-
tablish whether breastfeeding has been initiated and is
maintained. Mothers in the Healthy Conversation Skills
intervention group also have a Healthy Conversation
with a research nurse during which the mother’s goals
for herself and her baby are reviewed. As before, the
content of the conversation is recorded. All mothers are
asked whether they consent to be contacted in the future
if the study receives funding for a follow-up during
childhood.
Inclusion and exclusion criteria
Inclusion criteria
The inclusion criteria are as follows:
 Less than 17 weeks gestation at recruitment based
on last menstrual period (LMP)
 Aged over 18 years
 Singleton pregnancy
 Aiming to give birth at local maternity (Princess
Anne) hospital.
Exclusion criteria
The exclusion criteria are as follows:
 Known metabolic disease or chronic disease
associated with bone metabolism
 Current medication likely to interfere with
intrauterine growth
 Inability to give informed consent
 History of renal stores, hyperparathyroidism or
hypercalciuria
 A diagnosis of cancer in the last 10 years
 Serum calcium >2.75 mmol/l.
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Timing of pregnancy
Many women do not know the exact timing of concep-
tion. Thus, gestation based on the timing of a woman’s
last menstrual period (LMP) and that based on ultra-
sound scan often differ. Therefore, women coming for
their dating scan between 8 and 12 weeks might find
they are actually a few weeks earlier or later in their
gestation than they thought. All assessments will be
performed as closely as possible to the gestational timing
outlined in the protocol. Where this is not possible, the
following limits will be observed:
 Women with gestations between 8 and 17 weeks
can be included in the trial
 Dating scans take place between 8 and 12 weeks
 Nuchal translucency scans cannot be performed
before 11 weeks, and so women with pregnancies of
earlier gestation might be asked to return at 11 or
12 weeks
 Early pregnancy visits will be performed as closely as
possible to that time but will be acceptable until the
anomaly scan at 18–21 weeks
 The anomaly scan is performed between 18 and
21 weeks
 The 34 week scan will be performed between 33 and
36 weeks but, if delayed, can be performed up to
delivery
Sample size and power calculation
Our power calculation uses an alpha of 0.025 taking into
account the two primary outcomes of maternal vitamin
D and maternal diet quality. With 150 participants in
each arm of the trial (equivalent to 300 participants per
arm in each comparison between HCS and routine care
and between vitamin D and placebo) there is 80 % power
at an alpha of 0.025 to detect a 0.25 standard deviation
difference in both diet quality score and vitamin D
(approximately 3 nmol/l 25(OH)) between groups.
Allowing for a 20 % drop-out rate, we aim to recruit 188
women to each arm of the four arms of the trial in order
to achieve 150 women in each arm. Pilot data suggest
that around 40 % of women who are approached will
agree to participate in the study, and so initial invitations
will be issued to 1250 women. Experience in the MAVI-
DOS trial indicates that women will be recruited at a
rate of 5–8 per week, suggesting that recruitment will
take up to 3 years.
Statistical analyses
We will perform a complete case analysis for each
outcome using t tests to compare the two primary
outcomes between the relevant intervention arms. Mul-
tiple linear regression will be used to adjust for any
differences identified at baseline. Similar analyses will be
conducted for the secondary outcomes. The neonatal
bone and body composition analyses will include stratifi-
cation by season of birth in light of recent findings from
the MAVIDOS trial [10]. We will also conduct explora-
tory analyses of the interaction between HCS and vita-
min D on both primary outcomes. For binary outcomes,
chi-squared tests or Fisher’s exact test for rare outcomes
will be used. To adjust for imbalances at baseline, logis-
tic regression will be used, or for rare outcomes, binary
regression or Poisson regression with robust variance.
Process evaluation
In accordance with Medical Research Council (MRC)
guidance, our process evaluation will assess implementa-
tion, mechanisms of action and context [27]. It runs
throughout the trial. We have involved stakeholders, in-
cluding maternity and public health practitioners and
members of a lay advisory panel, in the development of
a logic model which describes the way in which the
intervention processes will bring about change in the
outcomes. Implementation is being assessed through
observation and recording of staff interactions with par-
ticipants and includes an assessment of Healthy Conver-
sation Skills research nurses’ competence in the skills
they have been taught and their confidence in the use of
these skills. Recruitment and retention of participants
will be monitored throughout the trial. Mechanisms of
action will be assessed through interviews with women
to find out their experiences of taking part in the trial
and, in particular, their experiences of contact with
nurses trained in Healthy Conversation Skills. We will
also examine intermediate outcomes, as we hypothesise
that change in diet will be facilitated by improvements
in women’s self-efficacy. In assessing context, we will
aim to identify any factor that might act as a barrier or
facilitator to intervention implementation or effects and
will carry out detailed mapping of local services and
national policy that might influence the delivery and
efficacy of the intervention.
Ethical considerations
Information sheets are given to participants outlining
the procedures that they will undergo, and plain English
is used to facilitate participants’ understanding of the
study. Participants also have opportunities, at each
follow-up appointment, to discuss any concerns with
study staff. The infant DXA assessments are associated
with a low dose of radiation exposure, roughly equivalent
to 2 days of background radiation in Cornwall (UK) and
7 days in other parts of the UK including Southampton.
The dose of vitamin D supplementation has been chosen
to bring women just into the normal range (>50 nmol/l
circulating 25-hydroxy vitamin D), to avoid elevating to
supranormal levels. This approach is consistent with that
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taken in the MAVIDOS trial of vitamin D supplementa-
tion during pregnancy [10]. Previous observational studies
in Southampton have suggested low risk of adverse effects
from vitamin D supplementation: data from the Princess
Anne Cohort study showed a small excess of atopic
asthma in children born to mothers with the highest levels
of vitamin D in pregnancy [28]. However, numbers of chil-
dren affected were lower than expected from general
population prevalence, and the confidence intervals
around the association were wide. No associations be-
tween atopy in infancy and high levels of maternal vitamin
D have been shown in the Southampton Women’s Survey,
and other studies have suggested neutral or negative asso-
ciations [29–31].
Blood and tissue samples will be processed for storage
on the day of collection and will be stored in freezers in
the MRC Lifecourse Epidemiology Unit, Southampton
General Hospital. They will be stored until all analyses
are completed. Professor Cyrus Cooper, Director of the
Unit and chief investigator for the SPRING trial, will
have custodial responsibility, and the samples will be
stored in compliance with Human Tissue Authority
(HTA) regulations.
There is a potential risk of distress with any interview.
Staff will be trained in interviewing techniques and will
terminate an interview in the rare event that questions
cause participants distress. If a participant should be-
come distressed, she will be reminded of the helpline
number and will be referred to support services, a list of
which will be available in the research clinic.
Reporting of adverse events
Anticipated adverse events
Some pregnancy-associated complications are expected to
arise spontaneously during the study and are not associ-
ated with vitamin D supplementation. These include cho-
lestasis of pregnancy, pregnancy-induced hypertension,
gestational diabetes, pre-eclampsia, eclampsia, premature
labour or delivery, instrumental delivery, Caesarean sec-
tion, miscarriage or stillbirth.
Adverse drug reactions and adverse drug events
Any adverse event which might be linked in any way to
vitamin D supplementation is immediately reported to
the sponsor. A detailed written report on the event is
produced. The principal investigator decides whether to
expedite reports of adverse events felt to be unrelated to
the IMP. A record of all serious adverse events is kept in
the trial site file.
The sponsor keeps detailed records of all adverse
events reported to them by the principal investigator.
These records may then be sent to the licensing
authority if required.
Suspected unexpected serious adverse reactions
The sponsor ensures that all relevant information about
suspected unexpected serious adverse reactions which
are fatal or life-threatening that occur during the course
of the trial are reported as soon as possible to the
Medicines and Healthcare products Regulatory Agency
(MHRA) and the relevant ethics and data monitoring
committees. This is done no later than 7 days after the
sponsor was first made aware of the reaction. Any
additional relevant information is sent to the MHRA
within 8 days of the initial report.
Suspected unexpected serious adverse reactions that
are not fatal or life-threatening are reported to the
MHRA and the relevant ethics/data monitoring commit-
tee no later than 15 days after the sponsor becomes
aware of them.
Data collection and management
To guarantee the validity and integrity of trial design
and conduct, two committees are being established. The
trial steering committee is overseeing trial design and
implementation. An independent data monitoring com-
mittee is overseeing the data collection process.
Regulatory aspects
The study has received approval from the MHRA,
Southampton and South West Hampshire Research
Ethics Committee, University Hospital Southampton R
and D (sponsor) and the UHS Data Protection Office.
The IMP and placebos are manufactured in accordance
with Good Manufacturing Practice (GMP) regulations.
The study is conducted in compliance with the Research
Governance Framework for Health and Social Care, the
Medicine for Human Use (Clinical Trials) Regulation
2004 and with Good Clinical Practice (GCP). Indemnity
has been provided through the University Hospital
Southampton NHS Foundation Trust (sponsor) and the
University of Southampton.
Discussion
Intervening to improve the nutritional status of pregnant
women will optimise the growth and development of their
babies, which will in turn reduce their risk of cardiovascu-
lar disease and obesity when they reach adulthood [1].
The combination of nutrient supplementation and behav-
ioural intervention being tested in SPRING represents a
multi-component approach that has the potential to ad-
dress vitamin deficiencies and to improve general quality
of diet. Research suggests that both are important in im-
proving outcomes for women and their babies. The factor-
ial design of this trial has the advantage of enabling each
intervention to be tested separately as well as allowing ex-
ploration of the synergistic effect of both interventions on
women’s diets and vitamin D levels.
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Trial status
The SPRING trial is ongoing.
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